Explain these topics Blood Pressure Regulation & Shock Cardiac Output (Regulation & Measurement) ECG (Normal waves, leads, blocks) Cardiac Cycle & Heart Sounds Hypoxia (Types & Distinguishing features) Surfactant & Respiratory Distress Syndrome O2-Hb Dissociation Curve & Shift Factors Neural/Chemical Regulation of Respiration Acclimatization at High Altitude Counter-Current Mechanism GFR & its Regulation Juxtaglomerular Apparatus (JGA) Micturition Reflex Renal Clearance (Inulin/Creatinine) Jaundice (Types & Pathophysiology) Coagulation Cascade & Hemophilia Blood Groups & Mismatched Transfusion Immunity (T/B cells & applied) Erythropoiesis Gastric HCI Secretion & Peptic Ulcer Pancreatic Juice Composition & Regulation Bile & Enterohepatic Circulation Deglutition

Reading File

Finding Sources

Reading File

Searching Images

cardiac cycle heart sounds pressure volume ECG diagram

This physiological waveform diagram displays a simultaneous recording of three cardiac parameters used for assessing cardiovascular hemodynamics. The top trace is an Electrocardiogram (ECG) showing standard QRS complexes representing ventricular depolarization. The middle trace is a Phonocardiogram (PCG) capturing acoustic vibrations of heart sounds, specifically the S1 and S2 sounds. The bottom trace is a Brachial Pulse Volume Waveform (bPVW) illustrating the peripheral arterial pressure pulse. Vertical markers indicate temporal relationships between these signals to calculate systolic time intervals. The 'QS2' interval is marked from the onset of the QRS complex on the ECG to the aortic component of the second heart sound on the PCG, representing the total electromechanical systolic interval. The 'bET' (Brachial Ejection Time) is delineated on the bPVW from the waveform foot to the dicrotic notch. An annotated formula shows the calculation of the Brachial Pre-ejection Period (bPEP) as the difference between QS2 and bET (bPEP = QS2 - bET). This diagram is an educational tool for understanding the non-invasive assessment of cardiac systolic function and arterial stiffness.

Summary : This figure illustrates the left atrial (LA) pressure-volume relationship during the cardiac cycle, showing both time-course traces and a pressure-volume loop, with key phases of atrial function annotated and correlated with the ECG. line plot and loop diagram: # Panel A: LA Pressure and Volume Traces • Top trace: LA Pressure (y-axis, arbitrary units) over time. • Middle trace: LA Volume (y-axis, arbitrary units) over time. • Bottom trace: ECG waveform for temporal reference. • X-axis: Cardiac cycle phases, with systole and diastole labeled; diastole further subdivided into E, D, and A phases. • Five phases are color-coded and numbered: – (1) Atrial filling (red) – (2) Passive emptying (green) – (3) Diastasis (black) – (4) Active emptying (blue) – (5) Atrial relaxation (gray) • Vertical dashed lines demarcate transitions between phases. # Panel B: LA Pressure-Volume Loop • X-axis: LA Volume (arbitrary units). • Y-axis: LA Pressure (arbitrary units). • The loop is traced in a counterclockwise direction, with arrows indicating the sequence. • The same five phases (1–5) are color-coded as in Panel A. • The loop is divided into two segments: A-Loop (phases 1, 3, 4, 5) and V-Loop (phase 2). # Design Encodings : • Distinct colors for each phase (red, green, black, blue, gray). • Arrows on the loop indicate the direction of the cardiac cycle. • ECG trace provides timing reference for the pressure and volume changes. # Analysis : • The LA pressure and volume traces show cyclical changes corresponding to atrial filling, emptying, and relaxation. • The pressure-volume loop visually summarizes the dynamic relationship between LA pressure and volume, with distinct segments for passive and active phases. • The figure highlights the temporal coordination between atrial events and the ECG, emphasizing the mechanical and electrical coupling in the cardiac cycle.

An educational anatomical and physiological diagram illustrating the synchronous collection of multiple cardiovascular biosignals in a canine model. The left side features a lateral-view anatomical illustration of a canine, highlighting the skeletal system, the heart, and major peripheral arteries. Four distinct biosignal waveforms are displayed on the right, with arrows tracing each to its anatomical point of acquisition: 1) LVBP (Left Ventricular Blood Pressure) signal, showing a rhythmic pressure waveform originating from the heart. 2) PPG (Photoplethysmogram) signal, a pulsatile volume waveform traced to the femoral artery. 3) ECG (Electrocardiogram) signal, showing characteristic P-QRS-T complexes with a prominent R-wave, traced to the forelimbs (Lead I configuration). 4) PCG (Phonocardiogram) signal, depicting high-frequency oscillations representing heart sounds, recorded from the cardiac apex. The diagram demonstrates the integration of invasive and non-invasive hemodynamic monitoring, useful for teaching comparative physiology and cardiovascular signal processing.

Searching Images

oxygen hemoglobin dissociation curve shift factors

This diagnostic image set displays two functional MR images (A and B) showing maternal-fetal units in a mouse model at embryonic days 14.5 and 17.5. The images feature overlaid color-coded AP50 maps, which represent fetal and placental oxygen-hemoglobin dissociation parameters. In both panels, the placenta and fetal liver are isolated as regions of interest. A vertical color bar on the right side indicates AP50 values scaled from 0 to 1.0, with cool colors (dark blue) representing lower values and warm colors (red/orange) representing higher values. Panel A (day 14.5) demonstrates a heterogeneous distribution of oxygenation parameters within the tissues, showing a mix of green, yellow, and blue pixels. Panel B (day 17.5) illustrates the progression of these physiological markers over time, with the placental AP50 values showing a significant spatial shift toward warmer colors, reflecting changes in oxygen transfer efficiency. These maps provide a non-invasive visual method for studying fetal oxygenation and placental function during gestation.

Summary : This figure illustrates the relationship between hemoglobin (Hb) level and oxygen delivery in individuals with sickle cell disease (SCD), highlighting the optimal Hb range for oxygen transport in SCD compared to normal individuals. line plot: # Title & Axes : • No explicit title on the plot, but the context is "Relationship between hemoglobin level and oxygen delivery in individuals with SCD." • X-axis: "Hemoglobin" (units not specified, but contextually g/dL). • Y-axis: "Oxygen delivery" (units not specified). • X-axis tick labels: 10, 15, 20. • Y-axis: No tick labels, only qualitative trend. # Data Points & Series : • Single red curve showing oxygen delivery as a function of hemoglobin level. • The curve rises from Hb = 10, peaks near Hb = 14–16, then declines toward Hb = 20. • Arrow and annotation for "Sickle Cell Anemia Hb_max ~10–11" indicating the optimal Hb range for SCD. • Dashed vertical line at "Normal Hb_max ~14–16" indicating the optimal Hb range for normal individuals. # Design Encodings : • Red solid line for the main curve. • Yellow arrow highlighting the SCD optimal Hb range. • Dashed vertical line for normal Hb_max. • Text annotations for "Sickle Cell Anemia Hb_max ~10–11" and "Normal Hb_max ~14–16". # Distribution & Trends : • The curve is unimodal, peaking at intermediate Hb levels. • Oxygen delivery increases with Hb up to a point, then decreases at higher Hb levels. • The optimal Hb for SCD is lower (~10–11 g/dL) than for normal individuals (~14–16 g/dL). # Analysis : • The figure visually demonstrates that the maximal oxygen delivery in SCD occurs at a lower hemoglobin level than in normal individuals, due to altered red cell viscosity and oxygen transport in SCD. • Increasing Hb above the SCD optimal range may decrease oxygen delivery, while lowering Hb to the optimal range can improve oxygen transport. • The curve supports clinical recommendations for transfusion targets in SCD patients to avoid excessive Hb levels that could impair oxygen delivery.

This composite diagnostic image displays Multispectral Optoacoustic Tomography (MSOT) scans of a lung xenograft tumor model in a mouse. The panel compares a control group (top row) with a CA4P-treated group (bottom row) at four time points: 0h, 1h, 3h, and 24h. The pseudocolor overlay represents hemoglobin oxygen saturation (%SO2) on a scale from 0% (dark blue/black) to 80% (bright red). Red indicates high oxyhemoglobin levels, while blue represents deoxyhemoglobin or blood-deficient areas. In the control group, the tumor exhibits persistent heterogeneous oxygenation (mixed red and blue) throughout the 24-hour period. In the CA4P group, the tumor undergoes a dramatic shift from high baseline oxygenation at 0h to a predominantly blue signal at 1h, 3h, and 24h. This visual transition demonstrates the pharmacodynamic effect of Combretastatin A-4 phosphate (CA4P) as a vascular disrupting agent (VDA), illustrating immediate and sustained vascular shutdown, resulting in acute tumor hypoxia and reduced perfusion. Scale bars represent 5 mm.

Searching Images

coagulation cascade intrinsic extrinsic pathway factors

$A comprehensive pathophysiology diagram illustrating the human coagulation cascade and the specific pharmacodynamic sites of action for various anticoagulants. The diagram is divided into three functional zones: the Intrinsic Pathway (blue), starting with Factor XII; the Extrinsic Pathway (red), initiated by Tissue Factor (TF) and Factor VII; and the Common Pathway (purple), where the pathways converge at Factor X. The cascade terminates in the conversion of Fibrinogen (I) to Fibrin (Ia), forming a fibrin clot. A secondary visual element depicts a platelet clot associated with the extrinsic pathway. Key clinical pharmacotherapeutic targets are marked with color-coded symbols: Warfarin inhibits Factors IX, VII, X, and II; Unfractionated Heparin (UHEP) + Antithrombin III (ATIII) inactivates Factors XIIa, XIa, IXa, Xa, and IIa; Low-Molecular-Weight Heparin (LMWHEP) and Fondaparinux target Factor Xa; Direct Factor Xa inhibitors act on Factor Xa; and Dabigatran acts as a direct thrombin inhibitor (Factor IIa). This schematic is designed for medical education regarding hemostasis and thromboprophylaxis.$

A comprehensive pathophysiology diagram illustrating the human coagulation cascade and the specific pharmacodynamic sites of action for various anticoagulants. The diagram is divided into three functional zones: the Intrinsic Pathway (blue), starting with Factor XII; the Extrinsic Pathway (red), initiated by Tissue Factor (TF) and Factor VII; and the Common Pathway (purple), where the pathways converge at Factor X. The cascade terminates in the conversion of Fibrinogen (I) to Fibrin (Ia), forming a fibrin clot. A secondary visual element depicts a platelet clot associated with the extrinsic pathway. Key clinical pharmacotherapeutic targets are marked with color-coded symbols: Warfarin inhibits Factors IX, VII, X, and II; Unfractionated Heparin (UHEP) + Antithrombin III (ATIII) inactivates Factors XIIa, XIa, IXa, Xa, and IIa; Low-Molecular-Weight Heparin (LMWHEP) and Fondaparinux target Factor Xa; Direct Factor Xa inhibitors act on Factor Xa; and Dabigatran acts as a direct thrombin inhibitor (Factor IIa). This schematic is designed for medical education regarding hemostasis and thromboprophylaxis.

Summary : This diagram illustrates the traditional coagulation cascade, detailing the sequence of events and factors involved in blood clotting via the intrinsic, extrinsic, and common pathways. flowchart: # Pathways : • Intrinsic pathway (green box): Initiated by factor XII, proceeds through XI, IX, and VIII, with activation steps indicated by "a" (e.g., XIIa, XIa, IXa). • Extrinsic pathway (red box): Initiated by tissue damage, which activates tissue factor (TF) and factor VIIa. • Common pathway (blue box): Both intrinsic and extrinsic pathways converge at factor X, leading to the activation of prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a fibrin clot. # Nodes : • XII → XIIa (Intrinsic) • XI → XIa (Intrinsic) • IX → IXa (Intrinsic) • Ca²⁺, PT, V (Intrinsic, Common) • TF/VIIa (Extrinsic) • Tissue damage (Extrinsic) • X → Xa (Common) • Prothrombin → Thrombin (Common) • Fibrinogen → Fibrin (Common) • XIII (Common) • Fibrin clot (Common) # Connectors : • Arrows indicate the direction of activation or conversion between factors. • Intrinsic and extrinsic pathways both feed into the activation of factor X in the common pathway. • Ca²⁺ and PT, V are required cofactors at specific steps. # Layout : • Three main colored sections: green (intrinsic, top left), red (extrinsic, top right), blue (common, bottom). • Flow proceeds from top (initiation) to bottom (clot formation). • Arrows show sequential activation and convergence of pathways. # Analysis : • The diagram clearly separates the intrinsic and extrinsic initiation mechanisms, both converging on the common pathway at factor X. • The cascade is highly sequential, with each activated factor catalyzing the next step. • Calcium ions (Ca²⁺) and phospholipids (PT) are essential cofactors at multiple steps. • The final outcome is the formation of a stable fibrin clot, highlighting the coordinated nature of the coagulation process.

Searching Images

ECG normal waves P QRS T leads

A standard 12-lead electrocardiogram (ECG) displayed on a red grid background, demonstrating a normal sinus rhythm at approximately 64 beats per minute. The tracing shows clearly visible, upright P waves preceding every QRS complex in leads I, II, and aVF, confirming sinus origin. The QRS complexes exhibit a normal duration and morphology with appropriate R-wave progression across the precordial leads (V1-V6). The ST segments are isoelectric throughout all leads, with no evidence of acute ST-elevation or depression. T waves are upright and symmetrical, appearing most prominent in leads V3 through V6. This diagnostic image represents the resolution of hyperkalemia-induced ECG changes (such as peaked T waves or bradyarrhythmias) following medical treatment and intracellular potassium shifting. The tracing is organized into four columns representing limb leads (I, II, III), augmented limb leads (aVR, aVL, aVF), and precordial leads (V1-V3, V4-V6), with rhythm strips for leads V1, II, and V5 provided at the bottom.

A standard twelve-lead electrocardiogram (ECG) printed on pink grid paper. The tracing displays a regular sinus rhythm with a visible P wave preceding every QRS complex. In the limb leads (I, II, III, aVR, aVL, aVF), the axis appears normal with upright T waves in leads I and II. The precordial leads (V1-V6) show a characteristic progression of QRS morphology; however, there is a notable presence of Q waves in leads V1, V2, and V3, which is consistent with an old or age-undetermined septal infarction. The R-wave progression is somewhat delayed. ST segments are generally isoelectric across most leads without evidence of acute ST-elevation myocardial infarction (STEMI) at this time. T waves are primarily upright and symmetric in the lateral precordial leads (V5-V6). The rhythm strip at the bottom (Lead II and V1) confirms a stable, regular rate and rhythm post-cardiac arrest. This diagnostic image serves as a baseline clinical tool for evaluating ischemic changes and conduction disturbances in patients with a history of cardiac events.

Searching Images

jaundice types bilirubin metabolism pathway

A metabolic network diagram illustrating the pathophysiological pathways of the Dampness-Heat Jaundice Syndrome (DHJS) model. The illustration is centered on a 'DHJS Rat' and the 'Alimentary system' (liver and gallbladder), with four octagonal 'Main pathway' boxes representing Carbohydrate, Lipid, Amino Acid, and Other Metabolism Disorders. Radiating from these nodes are numerous 'Sub-pathway' dashed boxes containing specific KEGG-based metabolic pathways, including Steroid Hormone Biosynthesis, Primary Bile Acid Biosynthesis, and Glycerophospholipid Metabolism. Key metabolites mentioned include bilirubin, cholic acid, corticosterone, and LysoPC. The diagram highlights 'Pathologic changes' such as Oxidative Stress and Hepatic Injury, indicated by thick purple arrows. Clinical biomarkers including TBil, TBA, ̳̳γ-GT, ALT, and MDA are shown with upward gray arrows, signifying elevation in the diseased state. This integrative map demonstrates the complex biochemical dysregulation across multiple systems associated with hepatic injury and bile secretion disorders.

A detailed pathophysiology diagram illustrating the metabolic pathway of heme degradation and its systemic physiological implications. The central panel displays the biochemical conversion of Heme to Biliverdin-IXα by the rate-limiting enzyme Heme Oxygenase-1 (requiring NADPH and 3O2), which releases carbon monoxide (CO) and ferrous iron (Fe II). Subsequently, Biliverdin-IXα is reduced to Bilirubin-IXα by Biliverdin Reductase using NADP(H). The diagram maps the downstream outcomes of these byproducts: CO is linked to vascular regulation, mitochondrial preservation, and immunomodulation through signaling molecules like p38 MAPK, NF-κB, and sGC. The 'Labile Iron Pool' is shown bifurcating into protective Ferritin sequestration or detrimental free radical catalysis. Bilirubin is associated with cellular and systemic antioxidant effects before undergoing hepatic conjugation via UDP-glucuronyl transferase for biliary excretion. Additionally, a 'Free Heme Pool' is noted for its role in TLR4-mediated inflammatory responses and endothelial injury. This clinical illustration serves as a comprehensive guide for medical students and researchers studying oxidative stress, heme metabolism, and cytoprotective mechanisms.

Reading File

Here is a comprehensive explanation of all 23 topics, organized by system.

Complete Physiology Notes: 23 High-Yield Topics

CARDIOVASCULAR SYSTEM

1. Blood Pressure Regulation & Shock

Blood Pressure = Cardiac Output × Total Peripheral Resistance (TPR)

Short-term regulation (seconds to minutes):

Baroreceptor reflex (most important): Stretch receptors in the carotid sinus and aortic arch detect pressure changes. A fall in BP → decreased baroreceptor firing → increased sympathetic output + decreased parasympathetic output → increased HR, contractility, vasoconstriction → BP restored.
Chemoreceptor reflex: Peripheral (carotid/aortic bodies) respond to low PO₂, high PCO₂, low pH. Central chemoreceptors respond to CO₂/H⁺ in CSF. Both cause reflex increase in BP.
CNS ischemic response (Cushing reflex): When cerebral perfusion falls critically, intense sympathetic discharge causes extreme hypertension + bradycardia (widened pulse pressure) - a last-ditch emergency response.

Long-term regulation (hours to days):

Renin-Angiotensin-Aldosterone System (RAAS): Low BP → renin (from JGA) → Angiotensin I → ACE → Ang II → vasoconstriction + aldosterone → Na⁺/H₂O retention → volume expansion.
ADH (Vasopressin): Released from posterior pituitary when plasma osmolarity rises or BP falls → water reabsorption in collecting duct.
Atrial Natriuretic Peptide (ANP): Released by atria when stretched → promotes Na⁺ excretion, reduces volume.

Shock - Inadequate tissue perfusion with cellular hypoxia. Classified as:

Type	Mechanism	Example	Key Feature
Hypovolemic	↓ preload (blood/fluid loss)	Hemorrhage, burns	↑ TPR, ↓ CO
Cardiogenic	Pump failure	MI, tamponade	↑ TPR, ↓ CO, ↑ CVP
Distributive	Vasodilation/maldistribution	Septic, anaphylactic, neurogenic	↓ TPR, warm skin
Obstructive	Obstruction to flow	Pulmonary embolism, tension pneumothorax	↑ TPR, ↓ CO

Stages of hemorrhagic shock:

Class I: <750 mL, <15% blood volume - compensated
Class II: 750-1500 mL, tachycardia, anxiety
Class III: 1500-2000 mL, confusion, hypotension
Class IV: >2000 mL, lethargy, life-threatening

Compensatory responses in shock: Sympathetic activation → tachycardia, vasoconstriction, release of catecholamines, cortisol, ADH, aldosterone → fluid retention. Prolonged shock → irreversible cell death, MODS.

2. Cardiac Output: Regulation & Measurement

CO = Stroke Volume (SV) × Heart Rate (HR)

Normal: ~5 L/min (70 mL × 72 bpm)
Cardiac Index = CO ÷ Body Surface Area = 2.5-4.0 L/min/m²
Ejection Fraction (EF) = SV ÷ End-Diastolic Volume (EDV) × 100 = normally 55-70%

Determinants of Stroke Volume:

Preload (end-diastolic volume/filling pressure): ↑ venous return → ↑ EDV → ↑ SV (Frank-Starling law). The greater the myocardial fiber stretch at end-diastole, the greater the force of contraction and SV ejected.
Afterload (aortic pressure / TPR): ↑ afterload → more energy spent in isovolumetric contraction → ↓ SV, ↑ end-systolic volume. Chronic afterload increase (hypertension) → concentric hypertrophy.
Contractility (inotropy): The intrinsic ability of the myocardium to develop force at a given preload/afterload.
- Positive inotropes: catecholamines (β₁), digoxin, Ca²⁺, increased HR (Bowditch staircase/treppe)
- Negative inotropes: hypoxia, acidosis, heart failure, β-blockers, most anesthetic agents

Frank-Starling Law - Stroke volume increases with end-diastolic volume. This ensures left and right heart outputs remain balanced. On a pressure-volume loop, increased preload shifts the loop rightward (wider = more stroke volume).

Measurement of CO:

Fick Principle (gold standard): CO = O₂ consumption ÷ (arterial O₂ content - venous O₂ content). Requires pulmonary artery catheter.
Thermodilution (most common clinically): Cold saline injected into right atrium; thermistor in pulmonary artery measures temperature change. CO calculated from Stewart-Hamilton equation.
Echocardiography (Doppler): Non-invasive; measures velocity of flow × cross-sectional area of aorta.
Indicator dilution (dye dilution): Indocyanine green injected; concentration-time curve analyzed.

3. ECG: Normal Waves, Leads, and Blocks

Standard 12-lead ECG showing normal sinus rhythm with clearly visible P waves, QRS complexes, and T waves

Normal ECG Waves:

P wave: Atrial depolarization (SA node → atria). Duration <0.12s, amplitude <0.25 mV in lead II.
PR interval: AV nodal delay (time from atrial to ventricular depolarization). Normal 0.12-0.20s.
QRS complex: Ventricular depolarization. Duration <0.12s (narrow). Q = initial septal depolarization (left→right); R = main ventricular depolarization; S = basal depolarization.
ST segment: Ventricular plateau phase (no net current). Should be isoelectric. Elevation = injury (STEMI); depression = ischemia.
T wave: Ventricular repolarization. Normally concordant with QRS. Peaked/tall T = hyperkalemia, early ischemia.
QT interval: Total ventricular electrical systole. Corrected QTc = QT ÷ √RR. Prolonged QTc (>440ms men, >460ms women) → risk of torsades de pointes.

The 12 Leads:

Limb leads (frontal plane):

Standard bipolar: I (left arm - right arm), II (left leg - right arm), III (left leg - left arm) → Einthoven's triangle
Augmented unipolar: aVR (right arm), aVL (left arm), aVF (left foot)

Precordial leads (horizontal plane):

V1-V2: Right ventricle/septum (V1 over 4th ICS, right sternal border)
V3-V4: Anterior wall
V5-V6: Lateral wall

Electrical axis: Normally -30° to +90°. Left axis deviation (-30° to -90°) = LBBB, left anterior fascicular block, inferior MI. Right axis deviation (+90° to +180°) = RBBB, RVH, lateral MI.

Heart Blocks:

Block	PR Interval	QRS	Clinical
1st degree AV	>0.20s, constant	Normal	Benign, no treatment
2nd degree Mobitz I (Wenckebach)	Progressive prolongation then dropped beat	Normal	AV node disease, generally benign
2nd degree Mobitz II	Constant PR, sudden dropped beat	Often wide	His-Purkinje disease, may need pacemaker
3rd degree (complete)	No relationship P-QRS	Wide escape rhythm	Complete AV dissociation, pacemaker required
RBBB	Normal PR	Wide QRS, rSR' in V1 ("rabbit ears"), wide S in I, V6	Right bundle lesion
LBBB	Normal PR	Wide QRS, broad R in I/V6, deep S in V1	Left bundle lesion; makes ECG uninterpretable for ischemia

4. Cardiac Cycle & Heart Sounds

The cardiac cycle has two main phases: systole (contraction/ejection) and diastole (relaxation/filling).

Phases of the Cardiac Cycle (Left Ventricle):

Isovolumetric Contraction: Mitral valve closes (S1), aortic valve still closed. Pressure rises rapidly with no change in volume. Starts at end of QRS.
Rapid Ejection: LV pressure exceeds aortic pressure → aortic valve opens → blood ejected rapidly. ~70% of SV ejected.
Reduced Ejection: Slower ejection as pressure begins to equalize.
Isovolumetric Relaxation: Aortic valve closes (S2), mitral still closed. Pressure falls rapidly with no volume change. Represents end-systole.
Rapid Ventricular Filling: LV pressure falls below LA pressure → mitral valve opens → rapid passive filling (~75% of total filling). S3 (if present) occurs here - normal in children/athletes, pathological if heard in adults (indicates poor compliance/CHF).
Reduced Filling (Diastasis): Slow passive filling phase.
Atrial Contraction ("Atrial Kick"): Contributes last 25% of filling. S4 occurs here if atrium contracts against a stiff/non-compliant ventricle (e.g., hypertensive heart disease, hypertrophic CMP).

Pressure Values:

Aorta: 120/80 mmHg
LV systole/diastole: ~120/8 mmHg
LA: 5-12 mmHg (mean ~8)
RV: 25/5 mmHg
PA: 25/10 mmHg (mean ~15)

Heart Sounds:

S1 (lub): Closure of mitral (M1) and tricuspid (T1) valves at onset of systole. M1 precedes T1. Loud in mitral stenosis, soft in mitral regurgitation.
S2 (dub): Closure of aortic (A2) and pulmonic (P2) valves at end of systole. A2 precedes P2. Physiological splitting: A2-P2 gap widens on inspiration (RV fills more, delayed P2). Fixed splitting = ASD. Paradoxical splitting (P2 before A2) = LBBB, severe AS.
S3 (ventricular gallop): Early diastole during rapid filling. Pathological in adults → LV failure, dilated CMP.
S4 (atrial gallop): Late diastole during atrial contraction against stiff ventricle. → LVH, aortic stenosis, hypertensive heart disease.

RESPIRATORY SYSTEM

5. Hypoxia: Types & Distinguishing Features

Hypoxia = inadequate O₂ delivery to or utilization by tissues.

Type	PaO₂	SaO₂	CaO₂	A-a gradient	Description	Example
Hypoxic hypoxia	↓	↓	↓	Normal or ↑	Low O₂ in blood due to low PaO₂	High altitude, hypoventilation, V/Q mismatch, diffusion defect
Anemic hypoxia	Normal	Normal	↓	Normal	Reduced Hb to carry O₂	Anemia, CO poisoning (Hb saturated but can't release O₂)
Stagnant (circulatory) hypoxia	Normal	Normal	Normal	Normal	Poor perfusion/delivery	Heart failure, shock, local ischemia
Histotoxic hypoxia	Normal	Normal	Normal	Normal	Cells cannot use O₂	Cyanide poisoning (blocks cytochrome c oxidase)

Key distinguishing features:

CO poisoning (type of anemic hypoxia): PaO₂ normal, but pulse oximeter reads falsely normal. Cherry-red skin. Carboxyhemoglobin (COHb) measured only by co-oximetry.
Cyanide (histotoxic): Venous PO₂ is HIGH (tissues can't extract O₂), no cyanosis.
Hypoxic hypoxia: responsive to supplemental O₂ (except shunt, which doesn't respond well).
Cyanosis appears when deoxyhemoglobin >5 g/dL in capillaries.

Alveolar-arterial (A-a) gradient = PAO₂ - PaO₂. Normal <15 mmHg (increases with age). Elevated in V/Q mismatch, diffusion defect, shunt. Normal in hypoventilation and high altitude.

6. Surfactant & Respiratory Distress Syndrome

Surfactant:

Produced by Type II pneumocytes (also called great alveolar cells or granular pneumocytes)
Composition: ~80% phospholipids (predominantly dipalmitoylphosphatidylcholine, DPPC), 10% proteins (SP-A, SP-B, SP-C, SP-D), 10% neutral lipids
SP-B and SP-C: critical for surface tension lowering
SP-A and SP-D: immune defense (opsonization)

Function: Reduces surface tension at the alveolar air-liquid interface. By LaPlace's Law: P = 2T/r. Without surfactant, smaller alveoli (smaller r) would collapse into larger ones. Surfactant reduces T disproportionately more in small alveoli, equalizing pressures and preventing atelectasis.

Surfactant production: Starts around 24-28 weeks gestation. Mature levels from ~35 weeks. Accelerated by corticosteroids (given antenatally to mothers <34 weeks).

Neonatal Respiratory Distress Syndrome (NRDS / Hyaline Membrane Disease):

Cause: Deficiency of surfactant in premature neonates
Mechanism: Low surfactant → high surface tension → alveolar collapse (atelectasis) → diffuse microatelectasis → V/Q mismatch → hypoxia → pulmonary vasoconstriction → plasma leaks into alveoli → hyaline membrane formation (fibrin + plasma proteins)
Features: Presents within hours of birth; tachypnea, grunting, nasal flaring, intercostal retractions, cyanosis
CXR: "Ground glass" opacity, air bronchograms, reticulogranular pattern
Treatment: Antenatal corticosteroids (betamethasone), exogenous surfactant replacement (beractant, poractant), CPAP/mechanical ventilation, O₂

Adult RDS (ARDS): Triggered by systemic injury (sepsis, trauma, aspiration) → diffuse alveolar damage → inflammation → leaky capillaries → protein-rich fluid in alveoli → surfactant inactivation → hypoxia refractory to O₂. Hallmark: PaO₂/FiO₂ ratio <300.

7. O₂-Hb Dissociation Curve & Shift Factors

The oxyhemoglobin dissociation curve plots %Hb saturation vs. PO₂ in blood. It is sigmoidal due to cooperative binding (each O₂ bound makes next binding easier - allosteric change in Hb quaternary structure).

Key points:

P₅₀ = PO₂ at which Hb is 50% saturated. Normal = ~26 mmHg.
Arterial blood: PO₂ ~100 mmHg → ~97-98% saturation
Mixed venous blood: PO₂ ~40 mmHg → ~75% saturation
Physiological significance: At the flat upper part, large changes in PO₂ produce minimal change in saturation (protects loading). At the steep middle section, small falls in PO₂ cause large O₂ unloading (facilitates tissue delivery).

Bohr Effect - Shift to the RIGHT (↓ affinity, ↑ P₅₀, more O₂ unloaded to tissues):

↑ PCO₂
↓ pH (acidosis)
↑ Temperature
↑ 2,3-DPG (2,3-bisphosphoglycerate - binds β-chains, stabilizes deoxy form)
Occurs at tissues (high CO₂, low pH) - adaptive: promotes O₂ unloading where needed

Shift to the LEFT (↑ affinity, ↓ P₅₀, less O₂ unloaded):

↓ PCO₂
↑ pH (alkalosis)
↓ Temperature
↓ 2,3-DPG
Fetal Hb (HbF) has γ-chains instead of β-chains; γ-chains bind 2,3-DPG poorly → HbF has higher O₂ affinity than HbA → facilitates O₂ transfer from maternal to fetal blood
CO poisoning (COHb shifts curve left AND reduces Hb available)

Myoglobin curve: Hyperbolic (single heme group, no cooperativity). Much higher affinity than Hb. P₅₀ ~2 mmHg. Serves as O₂ store in muscle, releases only at very low PO₂.

8. Neural & Chemical Regulation of Respiration

Central Respiratory Centers (Medullary):

Pre-Bötzinger complex (ventral respiratory group, VRG): Respiratory rhythm generator - generates automatic breathing rhythm. Contains inspiratory and expiratory neurons.
Dorsal respiratory group (DRG): Integrates sensory input; drives inspiration.
Ventral respiratory group (VRG): Active expiration and high-demand breathing.

Pontine Centers:

Pneumotaxic center (pontine respiratory group): Limits inspiration, promotes switch to expiration. Lesion → apneusis.
Apneustic center: Prolongs inspiration. Normally inhibited by pneumotaxic center.

Chemical Regulation:

Central chemoreceptors (ventral medullary surface):

Respond to PCO₂/H⁺ in CSF (CO₂ crosses BBB freely, forms H⁺ locally)
Most important in day-to-day regulation
Do NOT respond directly to O₂

Peripheral chemoreceptors (carotid bodies - IX nerve; aortic bodies - X nerve):

Respond primarily to PaO₂ (<60 mmHg stimulates strongly - hypoxic drive)
Also respond to ↑PCO₂, ↓pH (synergistic with central)
In COPD patients with chronic hypercapnia: central chemoreceptors adapt → hypoxic drive becomes dominant ("hypoxic drive" - be cautious with high-flow O₂)

Other Reflexes:

Hering-Breuer reflex: Pulmonary stretch receptors (slowly adapting) → when lungs inflate → inhibit inspiration (via vagus). Prevents over-inflation. Important in infants.
J receptors (juxtacapillary receptors): In alveolar walls, stimulated by pulmonary congestion/edema → rapid shallow breathing, dyspnea.
Irritant receptors (rapidly adapting): Bronchoconstriction, hyperpnea with irritants, cough.

PCO₂ is the dominant drive to breathe in normal subjects. Even a small rise in PCO₂ (1 mmHg) → significant increase in ventilation.

9. Acclimatization at High Altitude

At high altitude, atmospheric pressure falls but O₂% remains 21% → PO₂ falls → hypoxic stimulus.

Immediate responses (hours):

↑ Ventilation (hypoxic stimulation of peripheral chemoreceptors) → respiratory alkalosis (↓PCO₂)
↑ HR and CO (sympathetic stimulation)

Short-term (days 1-3):

Renal compensation: Kidneys excrete HCO₃⁻ to compensate respiratory alkalosis → pH normalizes → removes alkalotic braking on ventilation → ventilation increases further (most important step in acclimatization)
↑ 2,3-DPG in RBCs → rightward shift of O₂-Hb curve → facilitates O₂ unloading at tissues

Long-term (weeks):

↑ Erythropoietin (EPO) from peritubular cells of kidney (in response to hypoxia via HIF-1α) → ↑ erythropoiesis → ↑ Hb and hematocrit → ↑ O₂ carrying capacity (polycythemia)
↑ Pulmonary vascular resistance (hypoxic vasoconstriction is generalized at altitude) → RVH in some
↑ Capillary density in muscles
↑ Mitochondrial density and oxidative enzyme activity
Shift in Hb back to near normal (2,3-DPG effect partially offset by increased HbF synthesis)

Acute Mountain Sickness (AMS): Headache, nausea, fatigue, dizziness within 6-12 hours. Cerebral vasodilation + mild cerebral edema. Treated with descent, O₂, acetazolamide (carbonic anhydrase inhibitor → metabolic acidosis → stimulates breathing), dexamethasone.

High Altitude Pulmonary Edema (HAPE): Most dangerous acute complication; high pulmonary artery pressure + capillary leak.

RENAL SYSTEM

10. Counter-Current Mechanism

The counter-current mechanism allows production of concentrated or dilute urine. Located in the juxtaglomerular (juxtamedullary) nephrons with long loops of Henle.

Counter-Current Multiplier (Loop of Henle):

The ascending limb of the loop of Henle is impermeable to water but actively pumps NaCl out (via Na⁺-K⁺-2Cl⁻ cotransporter, NKCC2) → creates medullary hyperosmolarity (up to 1200 mOsm/kg at papilla).

Descending limb (thin): Permeable to water, impermeable to solutes → water leaves by osmosis into the hypertonic medulla → tubular fluid becomes concentrated.
Ascending limb (thick): Impermeable to water, actively transports NaCl out → tubular fluid becomes dilute (hypotonic ~100 mOsm at macula densa).

Urea recycling: Collecting duct (under ADH) is permeable to urea → urea diffuses into medullary interstitium → contributes ~500 mOsm to medullary gradient (inner medulla especially).

Counter-Current Exchange (Vasa Recta): Capillaries running parallel to loop in opposite directions. Passively pick up solute as they descend and release as they ascend → prevent "washing out" the medullary gradient without adding to it.

ADH (Vasopressin) effect: Acts on principal cells of collecting duct → inserts aquaporin-2 (AQP-2) water channels → water reabsorbed → concentrated urine. Without ADH → dilute urine (diabetes insipidus).

Maximum urine osmolarity: ~1200 mOsm/kg (vs plasma ~285 mOsm/kg).

11. GFR & Its Regulation

Glomerular Filtration Rate (GFR) = volume of plasma filtered by the glomeruli per unit time. Normal: ~125 mL/min (males); ~110 mL/min (females). Total filtration ~180 L/day but only ~1.5 L urine excreted.

Starling Forces governing filtration:

Net filtration pressure = (PGC - PBS) - (πGC - πBS)
- PGC = glomerular capillary hydrostatic pressure (~60 mmHg) → favors filtration
- PBS = Bowman space hydrostatic pressure (~15 mmHg) → opposes filtration
- πGC = glomerular capillary oncotic pressure (~28 mmHg) → opposes filtration
- πBS = Bowman space oncotic pressure (~0 mmHg) → favors filtration
- Net = 60 - 15 - 28 = ~17 mmHg favoring filtration

Filtration coefficient (Kf) = surface area × hydraulic permeability of glomerular membrane.

GFR = Kf × Net Filtration Pressure

Regulation:

Renal autoregulation (intrinsic, works between MAP 80-180 mmHg):
- Myogenic mechanism: ↑ BP → stretch → afferent arteriole contracts → maintains GFR
- Tubuloglomerular feedback (TGF): ↑ NaCl delivery to macula densa → ATP/adenosine released → afferent arteriole constricts → ↓ GFR (negative feedback)
Sympathetic nervous system: Renal vasoconstriction → ↓ GFR (shock, exercise, pain)
RAAS: Ang II → constricts efferent arteriole preferentially → maintains GFR when renal perfusion falls (ACE inhibitors block this → drop in GFR in renal artery stenosis)
Prostaglandins (PGE₂, PGI₂): Dilate afferent arteriole → maintain GFR when vasoconstricted. NSAIDs block this → ↓ GFR in volume-depleted patients.
ANP: Dilates afferent, constricts efferent → ↑ GFR.

12. Juxtaglomerular Apparatus (JGA)

The JGA is a specialized structure at the vascular pole of the glomerulus with three components:

Juxtaglomerular (granular) cells: Modified smooth muscle cells in the wall of the afferent arteriole. Contain secretory granules of renin. Mechanoreceptors: ↓ renal arterial pressure → renin release. Also receive sympathetic input (β₁ → renin release).
Macula densa: Specialized epithelial cells at the end of the thick ascending limb of the loop of Henle. Act as chemoreceptors: detect NaCl concentration in tubular fluid. ↓ NaCl delivery → stimulates renin release from granular cells (via prostaglandins, NO). Also mediate TGF.
Extraglomerular mesangial cells (Lacis cells): Between the arterioles and macula densa; communication and structural support; may relay signals.

Stimuli for renin release:

↓ Renal perfusion pressure (mechanical stretch of granular cells)
↓ NaCl at macula densa
↑ Sympathetic tone (β₁ adrenergic)

Inhibitors of renin release:

↑ BP, ↑ NaCl delivery
Ang II (negative feedback)
ADH

Renin cascade: Renin (enzyme) cleaves angiotensinogen (from liver) → Angiotensin I → ACE (in lung) → Angiotensin II → (1) vasoconstriction, (2) aldosterone release from adrenal cortex, (3) ADH release, (4) stimulates thirst, (5) feedback to JGA.

13. Micturition Reflex

Anatomy: Bladder = detrusor muscle (smooth muscle). Sphincters: internal urethral sphincter (smooth muscle, involuntary - sympathetic), external urethral sphincter (skeletal muscle, voluntary - somatic pudendal nerve).

Filling phase:

Sympathetic (T10-L2, hypogastric nerve): Relaxes detrusor (β₃) + contracts internal sphincter (α₁). Allows storage.
Somatic (pudendal nerve, S2-4): Voluntarily contracts external sphincter. Storage.
Sensory: As bladder fills (~150 mL first urge; ~400-500 mL strong urge), stretch receptors activate afferent signals (pelvic nerve → S2-S4).

Micturition reflex:

Bladder fills → stretch receptors in detrusor → afferent via pelvic nerve → spinal cord (S2-S4).
If socially appropriate: signal relayed to pontine micturition center (PMC, Barrington's nucleus) → descending pathway activates:
- Parasympathetic (pelvic nerve, S2-4): Contracts detrusor (M3 receptors)
- Relaxes internal sphincter
- Inhibition of pudendal nerve → external sphincter relaxes
Voiding occurs. Once started, voiding reinforced by additional stretch receptor activity (positive feedback until bladder empty).

Higher control:

PMC (pons): Coordinates sphincter relaxation with detrusor contraction (synergic voiding)
Periaqueductal gray (PAG): Relays bladder fullness to cortex
Frontal cortex: Voluntary suppression or initiation

Spinal cord injury above sacrum: Detrusor-sphincter dyssynergia (both contract together). Neurogenic bladder. Below S2-S4: Flaccid areflexic bladder.

14. Renal Clearance: Inulin & Creatinine

Clearance (C) = volume of plasma cleared of a substance per unit time. Formula: C = (U × V) ÷ P where U = urine concentration, V = urine flow rate (mL/min), P = plasma concentration.

Inulin clearance = GFR (reference standard)

Inulin is freely filtered, not secreted, not reabsorbed, not metabolized
Clearance = GFR = ~125 mL/min
If C > 125 → substance is secreted (e.g., PAH, creatinine)
If C < 125 → substance is reabsorbed (e.g., glucose, urea, Na⁺)

Creatinine clearance (CrCl):

Freely filtered + small amount tubular secretion → slightly overestimates GFR (~10-20%)
Used clinically because endogenous (no infusion needed)
Formula: CrCl = (U_Cr × V) ÷ P_Cr ≈ 125-130 mL/min
Cockcroft-Gault formula: Estimates GFR from serum creatinine, age, weight, sex
CKD-EPI / MDRD equations: More accurate estimation of eGFR in clinical practice

PAH (para-aminohippuric acid) clearance = Renal Plasma Flow (RPF)

Filtered + maximally secreted → all PAH extracted in one pass (if plasma level low)
PAH clearance (~625 mL/min) = Effective Renal Plasma Flow (ERPF)
Renal Blood Flow (RBF) = RPF ÷ (1 - hematocrit) ≈ 1200 mL/min
Filtration fraction = GFR ÷ RPF = 125/625 = 0.20 (20%)

Substances and their clearance patterns:

Substance	Filtered	Secreted	Reabsorbed	Clearance vs GFR
Inulin	Yes	No	No	= GFR (125)
Glucose (normal)	Yes	No	Completely	= 0
Urea	Yes	No	~50%	< GFR (~70)
Creatinine	Yes	Small	No	> GFR (~130)
PAH	Yes	Yes	No	>> GFR (~625)

GASTROINTESTINAL SYSTEM

15. Jaundice: Types & Pathophysiology

Bilirubin metabolism:

Heme (from RBC breakdown, 80%) → biliverdin → unconjugated (indirect) bilirubin (lipid-soluble, bound to albumin)
Liver: bilirubin taken up, conjugated with glucuronic acid by UDP-glucuronosyltransferase (UGT) → conjugated (direct) bilirubin (water-soluble)
Secreted in bile → intestine → bacteria convert to urobilinogen → some absorbed (enterohepatic circulation) → urobilin in urine; rest → stercobilin (brown stool color)

Feature	Pre-hepatic (Hemolytic)	Hepatic (Hepatocellular)	Post-hepatic (Obstructive)
Cause	Excess RBC breakdown	Liver cell damage	Bile duct obstruction
Examples	G6PD deficiency, sickle cell, ABO incompatibility	Viral hepatitis, cirrhosis, drug-induced	Gallstones, cholangiocarcinoma, pancreatic head cancer
Bilirubin type	↑↑ Unconjugated	↑ Both (predominantly conjugated)	↑↑ Conjugated
Urine bilirubin	Absent (unconjugated doesn't pass glomerulus)	Present	Present (bilirubinuria - "tea-colored urine")
Urobilinogen	↑↑ (excess production)	↓ or absent	Absent (no bile in intestine)
Stool color	Normal/dark	Pale	Pale/clay-colored (acholic)
AST/ALT	Normal	↑↑	Normal or mildly ↑
ALP/GGT	Normal	↑	↑↑
PT	Normal	Prolonged (liver can't synthesize factors)	Prolonged (corrects with Vit K - fat malabsorption)
Pruritus	Absent	Variable	Severe (bile salts deposited in skin)

Neonatal jaundice (physiological):

Appears day 2-3, resolves by day 7-10 (term)
Due to: immature UGT, ↑ RBC breakdown (fetal → adult Hb transition), increased enterohepatic circulation
Pathological if: <24h, >15 mg/dL, direct bilirubin >2 mg/dL, persists >2 weeks
Treatment: Phototherapy (blue light 460 nm converts unconjugated bilirubin to water-soluble isomers → excreted in urine/bile without conjugation)

Kernicterus: Unconjugated bilirubin (not bound to albumin) crosses BBB → deposits in basal ganglia → neurological damage.

16. Coagulation Cascade & Hemophilia

Coagulation cascade showing intrinsic and extrinsic pathways converging at Factor X

The coagulation cascade is a series of amplifying enzymatic reactions producing an insoluble fibrin clot. Each step involves an activated enzyme, an inactive substrate proenzyme, and a cofactor assembled on phospholipid surfaces of activated platelets. Calcium (binding γ-carboxylated glutamic acid residues on factors II, VII, IX, X) is essential at multiple steps.

Extrinsic Pathway (tissue factor pathway - primary in vivo):

Tissue factor (TF) exposed at injury site → binds Factor VII → TF-VIIa complex → activates Factor X (and IX)
Rapid but limited (inhibited by TFPI)
PT (prothrombin time) tests this pathway (factors VII, X, V, II, fibrinogen)

Intrinsic Pathway (contact activation - primarily a lab phenomenon, amplifies in vivo):

Factor XII + contact activation → XIIa → XIa → IXa + VIIIa → activates Factor X
PTT (partial thromboplastin time) tests this pathway (factors XII, XI, IX, VIII, X, V, II, fibrinogen)

Common Pathway:

Factor Xa + Va (on phospholipid surface + Ca²⁺) = prothrombinase complex → Prothrombin (II) → Thrombin (IIa)
Thrombin:
1. Fibrinogen → fibrin monomer → polymerizes
2. Factor XIII → XIIIa → cross-links fibrin (stable clot)
3. Activates V, VIII (positive feedback)
4. Activates Protein C (anticoagulant)
5. Activates platelets

Natural anticoagulants:

Antithrombin III (ATIII): Inhibits thrombin and Xa (potentiated 1000x by heparin)
Protein C + Protein S: Vitamin K-dependent; degrade Va and VIIIa (thrombomodulin + thrombin complex activates Protein C)
TFPI: Inhibits TF-VIIa and Xa
Prostacyclin (PGI₂) + NO from endothelium: Inhibit platelet aggregation

Hemophilia:

Feature	Hemophilia A	Hemophilia B	Hemophilia C
Deficient factor	VIII	IX	XI
Inheritance	X-linked recessive	X-linked recessive	Autosomal recessive
Prevalence	1:5,000-10,000 males	1:30,000 males	Rare
Lab: PT	Normal	Normal	Normal
Lab: PTT	Prolonged ↑↑	Prolonged ↑↑	Prolonged ↑
Treatment	Factor VIII concentrate / recombinant FVIII / DDAVP (mild)	Factor IX concentrate	FFP / Factor XI
Clinical	Hemarthrosis (joints), deep tissue bleeds, spontaneous bleeding	Same as A	Mild, after surgery/trauma

Von Willebrand Disease (most common inherited bleeding disorder):

Deficiency/dysfunction of vWF (carries FVIII, mediates platelet adhesion to collagen)
Mucocutaneous bleeding (epistaxis, menorrhagia)
Prolonged bleeding time, ↑ PTT (FVIII reduced), normal PT
Treated with DDAVP (desmopressin) - releases vWF from endothelium

17. Blood Groups & Mismatched Transfusion

ABO Blood Group System:

Blood Group	Antigen on RBC	Antibody in Plasma	Can donate to	Can receive from
A	A	Anti-B	A, AB	A, O
B	B	Anti-A	B, AB	B, O
AB	A and B	None (universal recipient)	AB only	All groups
O	None	Anti-A and Anti-B (universal donor for pRBCs)	All groups	O only

Rh Blood Group System:

Rh(D) antigen most clinically significant
Rh+: has D antigen (85% of population). Rh-: no D antigen.
Rh- individuals do NOT have anti-D antibodies naturally; they must be sensitized (exposure to Rh+ blood)
After sensitization: IgG anti-D produced → can cross placenta

Hemolytic Disease of the Newborn (HDN / Erythroblastosis Fetalis):

Rh- mother + Rh+ father → Rh+ fetus
First pregnancy: sensitization (small feto-maternal hemorrhage at delivery). No disease.
Second pregnancy: Memory B cells → rapid IgG anti-D production → crosses placenta → hemolysis of fetal RBCs → fetal anemia, hydrops fetalis, kernicterus
Prevention: Anti-D immunoglobulin (RhoGAM) given to Rh- mother at 28 weeks and within 72h of delivery → destroys fetal RBCs before sensitization can occur

ABO incompatibility (transfusion reaction): Giving wrong ABO blood → preformed IgM antibodies react immediately → intravascular hemolysis (complement-mediated):

Fever, chills, back/flank pain (most common early symptoms)
Hemoglobinuria (dark urine), jaundice
Hypotension, DIC, acute renal failure (hemoglobin precipitates in tubules)
Immediate management: Stop transfusion, IV fluids, monitor urine output, check labs (direct Coombs, LDH, haptoglobin, bilirubin)

18. Immunity: T/B Cells & Applied

Innate Immunity: Non-specific, rapid, no memory. Includes barriers, phagocytes (neutrophils, macrophages), NK cells, complement, cytokines. Pattern recognition via Toll-like receptors (TLRs) recognize PAMPs.

Adaptive Immunity: Specific, slower, has memory (basis of vaccination).

B Lymphocytes (Humoral Immunity):

Mature in bone marrow, express surface immunoglobulin (BCR = IgM or IgD)
Antigen binding → proliferation → differentiation into:
- Plasma cells: Secrete antibodies (IgM, IgG, IgA, IgE, IgD)
- Memory B cells: Rapid response to re-exposure
T-dependent antigens: Require T helper cell (CD4+) cooperation → isotype switching, affinity maturation (in germinal centers)
T-independent antigens (polysaccharides): Direct B cell activation; mainly IgM, poor memory (reason why polysaccharide vaccines poorly immunogenic in <2 years)

Antibody classes:

IgM: First produced in primary response; pentameric; good complement activator; ABO blood group antibodies
IgG: Most abundant; crosses placenta; secondary response; opsonization; most versatile
IgA: Secretory (dimer in secretions via J chain); mucosal immunity (tears, saliva, breast milk, GI/respiratory mucosa)
IgE: Binds mast cells/basophils; type I hypersensitivity (allergy), anti-parasitic
IgD: On naive B cell surface; role unclear

T Lymphocytes (Cell-Mediated Immunity):

Mature in thymus (positive selection on MHC, negative selection to remove self-reactive)
Require antigen presented with MHC (two signals needed to avoid anergy)

CD4+ T helper cells (recognize antigen + MHC class II on APCs):

Th1: IL-12 induced; secrete IFN-γ, IL-2 → activate macrophages → intracellular pathogens (TB, fungi), delayed hypersensitivity (Type IV)
Th2: IL-4 induced; secrete IL-4, IL-5, IL-13 → B cell class switching to IgE, eosinophil activation → allergy, parasites
Th17: IL-6 + TGF-β; secrete IL-17 → neutrophil recruitment → extracellular bacteria/fungi
T regulatory (Treg): IL-10, TGF-β → suppress immune responses → prevent autoimmunity

CD8+ T cytotoxic cells (recognize antigen + MHC class I on all nucleated cells):

Kill virus-infected cells and tumor cells via perforin/granzymes and Fas-FasL pathway
Require CD4+ help for full activation (CD40L-CD40 interaction)

Applied:

DiGeorge syndrome: Thymic aplasia → no T cells → recurrent infections, hypocalcemia (parathyroid aplasia), cardiac defects. 22q11 deletion.
Bruton's agammaglobulinemia: X-linked; Btk gene mutation → no mature B cells; recurrent bacterial infections after 6 months.
SCID (Severe Combined Immunodeficiency): No T or B cells; ADA deficiency (most common AR form), RAG mutations. Presents with PCP, candidiasis, recurrent infections.
HIV: Destroys CD4+ T cells → falls <200/μL → AIDS → opportunistic infections.
MHC restriction: T cells only recognize peptide in context of self-MHC (discovered by Zinkernagel and Doherty).

19. Erythropoiesis

Definition: Production of red blood cells (erythrocytes).

Sites by age:

Fetus: Yolk sac (0-2 months) → Liver/Spleen (2-7 months) → Bone marrow (5-9 months)
Birth to 5 years: All bones
Adults: Red marrow of axial skeleton (sternum, vertebrae, ribs, pelvis) + proximal long bone epiphyses
Extramedullary hematopoiesis (liver, spleen) resumes in pathological states (myelofibrosis, thalassemia)

Developmental stages (bone marrow → blood): Pluripotent stem cell (HSC) → BFU-E → CFU-E → Proerythroblast → Basophilic erythroblast → Polychromatic erythroblast → Orthochromatic erythroblast (nucleus extruded) → Reticulocyte (RNA still present, exits marrow) → Mature RBC (no nucleus, no organelles)

Reticulocyte: Stains with brilliant cresyl blue (residual RNA). Normal 1-2% of RBCs. Elevated in hemolysis or response to treatment = good bone marrow response.
Maturation time: ~5 days in marrow, 1-2 days as reticulocyte in blood.

Regulation:

Erythropoietin (EPO): Produced by peritubular interstitial cells (fibroblasts) of renal cortex (>90%); small amount by liver. Stimulated by hypoxia (via HIF-1α). Acts on CFU-E → promotes proliferation, differentiation, inhibits apoptosis.
Iron: Essential for heme synthesis. Absorbed as Fe²⁺ (ferrous) in duodenum (facilitated by vitamin C, decreased by tea/phytates). Transported by transferrin, stored as ferritin (or hemosiderin).
Vitamin B12 (cobalamin): Essential for DNA synthesis (thymidine synthesis via folate pathway). Absorbed in terminal ileum with intrinsic factor (IF) from gastric parietal cells.
Folic acid: Essential for purine and thymidine synthesis. Absorbed in jejunum.

Hemoglobin switching:

Embryo: Hb Gower (ζ₂ε₂), Portland (ζ₂γ₂)
Fetus: HbF (α₂γ₂) - high O₂ affinity
Adult: HbA (α₂β₂) - 97%; HbA₂ (α₂δ₂) - 2.5%; HbF <1%

20. Gastric HCl Secretion & Peptic Ulcer

Gastric acid secretion by Parietal cells (oxyntic cells):

Stimulants:

Acetylcholine (ACh) (vagal, M₃ receptors) → ↑ intracellular Ca²⁺ → H⁺-K⁺-ATPase activation
Gastrin (from G cells of antrum/duodenum, via blood, CCK₂ receptors) → ↑ Ca²⁺ → H⁺-K⁺-ATPase
Histamine (from ECL cells via paracrine, H₂ receptors) → ↑ cAMP → PKA → H⁺-K⁺-ATPase

The H⁺-K⁺-ATPase (proton pump): Actively pumps H⁺ out of parietal cell into lumen in exchange for K⁺. Generates intraluminal pH of ~1.0-2.0. Target of PPIs (proton pump inhibitors like omeprazole - irreversibly inhibit H⁺-K⁺-ATPase; bind only in active form, hence taken before meals).

Phases of gastric secretion:

Cephalic phase (~30% of total): Sight, smell, taste, thought of food → vagal stimulation → ACh → gastric acid and pepsinogen
Gastric phase (~60% of total): Food enters stomach → gastric distension → antral G cell stimulation → gastrin → acid secretion
Intestinal phase (~10%): Initial stimulation by entry of food into duodenum, then inhibition by secretin, CCK, GIP (when acid enters duodenum)

Inhibition of gastric acid: Low pH in antrum → somatostatin from D cells → inhibits G cells and parietal cells. Secretin (from S cells of duodenum, released by acid/fat) inhibits acid, stimulates pancreatic HCO₃⁻.

Peptic Ulcer Disease (PUD):

Imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and defensive factors (mucus-bicarbonate layer, prostaglandins, mucosal blood flow, tight junctions)
H. pylori: Gram-negative spiral bacillus. Urease produces NH₃ → neutralizes local acid → survives. VacA toxin + CagA → mucosal damage, inflammation. Found in 90% of duodenal ulcers, 70% of gastric ulcers.
NSAIDs: Inhibit COX-1 → ↓ PGE₂ and PGI₂ → ↓ mucus/HCO₃⁻ secretion, ↓ mucosal blood flow, ↑ acid secretion
Duodenal ulcer (DU): Excess acid; associated with H. pylori, blood group O; pain relieved by food
Gastric ulcer (GU): Mucosal barrier defect; pain worsened by food; must biopsy to rule out malignancy
Treatment: PPI + clarithromycin + amoxicillin (triple therapy for H. pylori); sucralfate; misoprostol (PGE₁ analogue for NSAID prophylaxis)

21. Pancreatic Juice: Composition & Regulation

Composition:

Volume: ~1-2 L/day
pH: 7.6-8.2 (alkaline, due to HCO₃⁻)
Enzymes (from acinar cells):
- Proteases (secreted as INACTIVE zymogens): Trypsinogen (activated by enterokinase/enteropeptidase on duodenal brush border → trypsin → activates all other zymogens), Chymotrypsinogen, Proelastase, Procarboxypeptidases
- Lipases (active when secreted): Pancreatic lipase (requires colipase), phospholipase A₂ (secreted as zymogen), cholesterol esterase
- Amylase (active when secreted): Cleaves starch → maltose + oligosaccharides
- DNase, RNase
HCO₃⁻ (from ductal cells): Neutralizes gastric acid, optimizes pH for enzyme activity

Regulation:

Stimulus	Hormone	Source	Effect on Pancreas
Acid in duodenum	Secretin	S cells of duodenum	↑↑ HCO₃⁻ and water (mainly ductal)
Fat + protein in duodenum	CCK (cholecystokinin)	I cells of duodenum	↑↑ Enzyme secretion (acinar cells) + gallbladder contraction
Vagal (cephalic phase)	ACh	-	↑ Enzyme secretion
Gastrin	G cells	-	Mild ↑ in enzyme secretion

Secretin-pancreozymin test: Gold standard for exocrine pancreatic insufficiency.

Pancreatitis mechanism: Premature activation of trypsinogen inside acinar cells (by lysosomal cathepsin B, bile reflux, alcohol, gallstones) → autodigestion → inflammation. Trypsin then activates all other zymogens → cascade of injury.

22. Bile & Enterohepatic Circulation

Bile composition:

Bile acids (primary: cholic acid, chenodeoxycholic acid - synthesized from cholesterol in liver; conjugated with glycine/taurine = bile salts)
Phospholipids (mainly lecithin/phosphatidylcholine)
Cholesterol (unconjugated)
Bilirubin (conjugated glucuronide)
Water + electrolytes

Functions of bile:

Emulsification of fats → increases surface area for pancreatic lipase
Micelle formation with fatty acids → facilitates absorption (mixed micelles)
Excretion of bilirubin, cholesterol, drugs, heavy metals

Bile acid synthesis: Cholesterol → primary bile acids (cholic + chenodeoxycholic) → conjugated with glycine/taurine → secreted in bile. Intestinal bacteria dehydroxylate → secondary bile acids (deoxycholic from cholic; lithocholic from chenodeoxycholic).

Enterohepatic Circulation:

Conjugated bile salts secreted into bile → stored in gallbladder → released into duodenum after eating (CCK trigger)
Travel with chyme → terminal ileum: active reabsorption (Na⁺-coupled cotransporter, IBAT/ASBT) → portal blood → liver → re-secreted into bile
Only ~5% lost in stool (fecal excretion) → replenished by de novo synthesis
Pool recycled 6-10 times per day; total pool ~3-5g but 15-30g secreted/day
Interruption (ileal resection, Crohn's) → bile acid deficiency → fat malabsorption + steatorrhea + fat-soluble vitamin deficiency (A, D, E, K)
Cholestyramine: Binds bile acids in intestine → interrupts EHC → ↓ cholesterol (used in hypercholesterolemia)

Gallstone formation (cholelithiasis):

Cholesterol stones (80%): Supersaturation of cholesterol (excess cholesterol secretion, deficient bile acids/lecithin, gallbladder stasis)
Pigment stones (20%): Hemolysis → excess unconjugated bilirubin → precipitates with Ca²⁺

23. Deglutition (Swallowing)

Deglutition is the process of moving food from mouth to stomach. It has 3 phases:

Phase 1 - Oral (Voluntary):

Food formed into bolus; tongue pushes bolus posteriorly against palate
Voluntary initiation; cerebral cortex control
Lips sealed, teeth together, soft palate rises to close nasopharynx

Phase 2 - Pharyngeal (Involuntary/Reflex):

Bolus touches posterior pharyngeal wall → triggers involuntary swallowing reflex
Coordinated by swallowing center in medullary reticular formation (via CN V, VII, IX, X, XII)
Sequence:
1. Soft palate elevates → closes nasopharynx (prevents nasal regurgitation)
2. Vocal cords approximate, epiglottis folds over larynx → airway protected
3. Breathing is inhibited (swallowing apnea)
4. Upper esophageal sphincter (UES) relaxes → bolus enters esophagus
This phase takes <2 seconds

Phase 3 - Esophageal (Involuntary):

Primary peristalsis: Continues wave from pharynx; propels bolus down esophagus (~8-10 cm/s for liquids, slower for solids)
Secondary peristalsis: Triggered by esophageal distension (if residue remains); clears remaining bolus
Lower esophageal sphincter (LES): Relaxes ahead of the peristaltic wave (mediated by VIP and NO) → allows bolus into stomach
After bolus passes: LES contracts (cholinergic, substance P, motilin) → prevents reflux

Nervous control:

Striated muscle (upper 1/3 esophagus): Somatic control via vagus (nucleus ambiguus)
Smooth muscle (lower 2/3 esophagus): Autonomic via vagus (dorsal motor nucleus) + enteric nervous system (myenteric/Auerbach plexus)

Clinical:

Achalasia: Failure of LES to relax + loss of peristalsis (degeneration of myenteric plexus Auerbach neurons, e.g., Trypanosoma cruzi in Chagas). Dysphagia to both solids and liquids.
GERD: Inappropriate LES relaxation → acid reflux. Risk increased by fatty foods, alcohol, nicotine, pregnancy, obesity. Treated by PPIs, H₂ blockers, antacids.
Dysphagia to solids only → mechanical obstruction (cancer, stricture, Schatzki ring)
Dysphagia to both solids and liquids from outset → motility disorder

Sources: Costanzo Physiology 7th Edition; Miller's Anesthesia 10th Ed; Robbins & Cotran Pathologic Basis of Disease; Basic Medical Biochemistry 6th Ed.

This is a shared conversation. Sign in to Orris to start your own chat.